Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are ...

The median progression-free survival was not reached among patients treated with Retevmo at the time of data analysis versus 16.8 months among patients treated with Cabometyx or Caprelsa. According to ...

The secret to the company's success is Cabometyx, a cancer medicine that continues to impress. Cabometyx is the top-prescribed therapy of its type in renal cell carcinoma (kidney cancer).